BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35690645)

  • 21. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
    Morishita S
    Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.
    Willekens C; Laplane L; Dagher T; Benlabiod C; Papadopoulos N; Lacout C; Rameau P; Catelain C; Alfaro A; Edmond V; Signolle N; Marchand V; Droin N; Hoogenboezem R; Schneider RK; Penson A; Abdel-Wahab O; Giraudier S; Pasquier F; Marty C; Plo I; Villeval JL; Constantinescu SN; Porteu F; Vainchenker W; Solary E
    Leukemia; 2023 Jun; 37(6):1287-1297. PubMed ID: 37100881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia.
    Tatarian J; Tupper N; Li P; Feusier J; Abdo M; Hyter S; Gonzales PR; Zhang D; Woodroof J; Kelting S; Godwin AK; Cui W
    Am J Clin Pathol; 2023 Nov; 160(5):490-499. PubMed ID: 37458189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
    Shuai W; Zuo Z; Li N; Garces S; Jelloul FZ; Ok CY; Li S; Xu J; You MJ; Wang W; Rehder C; Jabbour EJ; Patel KP; Medeiros LJ; Yin CC
    Cancer; 2023 Mar; 129(6):878-889. PubMed ID: 36583229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Pathogenesis of Myeloproliferative Neoplasms.
    Rolles B; Mullally A
    Curr Hematol Malig Rep; 2022 Dec; 17(6):319-329. PubMed ID: 36336766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent insights regarding the molecular basis of myeloproliferative neoplasms.
    Jang MA; Choi CW
    Korean J Intern Med; 2020 Jan; 35(1):1-11. PubMed ID: 31778606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
    Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
    Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
    Zhang L; Dong H
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
    Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
    Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
    Aguirre LE; Jain A; Ball S; Ali NA; Volpe VO; Tinsley-Vance S; Sallman D; Sweet K; Lancet J; Padron E; Yun S; Kuykendall A; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):459-467. PubMed ID: 38548563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
    Al-Ghamdi YA; Lake J; Bagg A; Thakral B; Wang SA; Bueso-Ramos C; Masarova L; Verstovsek S; Rogers HJ; Hsi ED; Gralewski JH; Chabot-Richards D; George TI; Rets A; Hasserjian RP; Weinberg OK; Parilla M; Arber DA; Padilla O; Orazi A; Tam W
    Mod Pathol; 2023 Mar; 36(3):100016. PubMed ID: 36788093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
    Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
    Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
    Vainchenker W; Kralovics R
    Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
    Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
    Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
    Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
    Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Venton G; Courtier F; Charbonnier A; D'incan E; Saillard C; Mohty B; Mozziconacci MJ; Birnbaum D; Murati A; Vey N; Rey J
    Am J Hematol; 2018 Mar; 93(3):330-338. PubMed ID: 29148089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical application of gene mutation information in myeloproliferative neoplasms].
    Takenaka K
    Rinsho Ketsueki; 2019; 60(6):610-618. PubMed ID: 31281152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.